Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OCGN – Ocugen, Inc.

Ocugen, Inc.
OCGN
$0.9224
Name : Ocugen, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $269,369,408.00
EPSttm : -0.2
finviz dynamic chart for OCGN
Ocugen, Inc.
$0.9224
6.27%
$0.0617

Float Short %

22.73

Margin Of Safety %

Put/Call OI Ratio

0.1

EPS Next Q Diff

-0.01

EPS Last/This Y

-0.03

EPS This/Next Y

-0.01

Price

1.02

Target Price

6.5

Analyst Recom

1

Performance Q

35.94

Relative Volume

10.04

Beta

4.22

Ticker: OCGN




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02OCGN0.83780.070.1436104
2025-06-03OCGN0.85210.070.0136694
2025-06-04OCGN0.880.070.0136944
2025-06-05OCGN0.95290.070.1336763
2025-06-06OCGN1.060.080.1237899
2025-06-09OCGN1.080.080.0238488
2025-06-10OCGN1.140.080.0138757
2025-06-11OCGN1.170.080.0139206
2025-06-12OCGN1.1950.070.0644650
2025-06-13OCGN1.140.070.1045259
2025-06-16OCGN1.1550.070.1645737
2025-06-17OCGN1.0850.080.0646200
2025-06-18OCGN1.0850.080.0447340
2025-06-20OCGN1.0450.080.0447204
2025-06-23OCGN0.98090.080.4142283
2025-06-24OCGN1.0350.090.2443162
2025-06-25OCGN1.040.090.8443918
2025-06-26OCGN1.0250.090.4644113
2025-06-27OCGN1.010.100.0144411
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02OCGN0.83-41.7- -0.23
2025-06-03OCGN0.85-41.7- -0.23
2025-06-04OCGN0.88-41.7- -0.23
2025-06-05OCGN0.95-41.7- -0.23
2025-06-06OCGN1.06-41.7- -0.23
2025-06-09OCGN1.09-41.7- -0.23
2025-06-10OCGN1.13-41.7- -0.23
2025-06-11OCGN1.17-41.7- -0.23
2025-06-12OCGN1.20-41.7- -0.23
2025-06-13OCGN1.14-41.7- -0.23
2025-06-16OCGN1.15-41.7- -0.23
2025-06-17OCGN1.09-41.7- -0.23
2025-06-18OCGN1.09-41.7- -0.23
2025-06-20OCGN1.06-41.7- -0.23
2025-06-23OCGN0.98-41.7- -0.23
2025-06-24OCGN1.03-41.7- -0.23
2025-06-25OCGN1.03-41.7- -0.23
2025-06-26OCGN1.02-41.7- -0.23
2025-06-27OCGN1.02-41.7- -0.23
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02OCGN0.197.2424.27
2025-06-03OCGN0.007.2424.27
2025-06-04OCGN0.007.2424.27
2025-06-05OCGN0.007.2424.27
2025-06-06OCGN0.007.2424.27
2025-06-09OCGN0.007.2324.27
2025-06-10OCGN0.007.2324.27
2025-06-11OCGN0.007.2323.88
2025-06-12OCGN0.007.2323.88
2025-06-13OCGN0.007.2323.88
2025-06-16OCGN0.006.9723.88
2025-06-18OCGN0.006.9723.88
2025-06-20OCGN0.006.9723.88
2025-06-23OCGN0.006.9723.88
2025-06-24OCGN0.006.9723.88
2025-06-25OCGN0.006.9723.88
2025-06-26OCGN0.006.9722.73
2025-06-27OCGN0.006.9722.73
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.05

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

Institutional Transactions

6.97

Beta

4.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

6

Growth Score

21

Sentiment Score

4

Actual DrawDown %

94.6

Max Drawdown 5-Year %

-97.7

Target Price

6.5

P/E

Forward P/E

PEG

P/S

63.58

P/B

18.06

P/Free Cash Flow

EPS

-0.19

Average EPS Est. Cur. Y​

-0.23

EPS Next Y. (Est.)

-0.25

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1160.86

Relative Volume

10.04

Return on Equity vs Sector %

-385.1

Return on Equity vs Industry %

-367.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Ocugen, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 95
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
stock quote shares OCGN – Ocugen, Inc. Stock Price stock today
news today OCGN – Ocugen, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCGN – Ocugen, Inc. yahoo finance google finance
stock history OCGN – Ocugen, Inc. invest stock market
stock prices OCGN premarket after hours
ticker OCGN fair value insiders trading